Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bretisilocin in healthy adult Japanese, Han Chinese, and Non-Asian volunteers
NCT07604558Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of bretisilocin (3 arms), sponsored by AbbVie Inc. Primary endpoint: Number of Participants Experiencing Adverse Events at 32 days. Started May 2026; status: completed.
02
Drugs
bretisilocin
Beyond the preview
Go deeper on NCT07604558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604558.